Table 8. In Vivo Efficacy of Selected Compounds in an L. donovani Hamster Model of VL Following BID Dosing for 5 and 10 Daysa.
| reduction
in parasite burden, % |
|||||||
|---|---|---|---|---|---|---|---|
| liver |
spleen |
bone
marrow |
|||||
| compound | dose (mg/kg), BID | 5 days | 10 days | 5 days | 10 days | 5 days | 10 days |
| 23 | 25 | n.d. | 99.9 | n.d. | 99.8 | n.d. | 99.6 |
| 50 | 99.3 | n.d. | 98.6 | n.d. | 83.4 | n.d. | |
| 28 | 25 | 95.9 | n.d. | 95.9 | n.d. | 94.5 | n.d. |
| 50 | 99.9 | n.d. | 100 | n.d. | 100 | n.d. | |
a
n = 6 animals per group, results were expressed as a percentage reduction in amastigote burden compared to vehicle-treated, infected control animals, n.d., not determined.